AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8667198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1813974 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Number of subjects: 0
Study 1813974 — intervention group
Group type: COMPARATOR
Intervention: bromocriptine
Number of subjects: 0
Study 1813974 — intervention group
Group type: COMPARATOR
Intervention: placebo (de novo patients)
Number of subjects: 0
Study 6410589 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 60
Study 6410589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30952795 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI-dTMS
Number of subjects: 98
Study 30952795 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-dTMS
Number of subjects: 98
Study 30952795 — intervention group
Group type: COMPARATOR
Intervention: Sham-dTMS
Number of subjects: 98
Study 29743090 — intervention group
Group type: COMPARATOR
Intervention: Standard Provider Training Only
Number of subjects: 590
Study 29743090 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Provider Training + Leader Training
Number of subjects: 590
Study 29743090 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Provider Training
Number of subjects: 590
Study 29743090 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Provider Training + Leader Training
Number of subjects: 590
Study 25615706 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - participated in a physical conditioning program throughout pregnancy, 55‐ to 60‐minute sessions, 3 days per week
Number of subjects: 166
Study 25615706 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - no specific intervention mentioned
Number of subjects: 166
Study 24402391 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) program featuring aerobic, strength, balance, and flexibility training
Number of subjects: 177
Study 24402391 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) program
Number of subjects: 177
Study 24402391 — intervention group
Group type: COMPARATOR
Intervention: Successful Aging (SA) educational program
Number of subjects: 177
Study 21920484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 60
Study 21920484 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) energy
Number of subjects: 60
Study 20943877 — intervention group
Group type: EXPERIMENTAL
Intervention: V710 30 μg
Number of subjects: 124
Study 20943877 — intervention group
Group type: EXPERIMENTAL
Intervention: V710 90 μg
Number of subjects: 124
Study 20943877 — intervention group
Group type: COMPARATOR
Intervention: V710 5 μg
Number of subjects: 124
Study 20943877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 124
Study 17559843 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of embryo culture supernatant (ECS)
Number of subjects: 48
Study 15880336 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF +405 CC genotype
Number of subjects: 596
Study 15880336 — intervention group
Group type: COMPARATOR
Intervention: VEGF +405 GG genotype
Number of subjects: 596
Study 15880336 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF -460 polymorphism
Number of subjects: 596
Study 12352783 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9578996 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood education
Number of subjects: 38
Study 9578996 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Start
Number of subjects: 38
Study 9578996 — intervention group
Group type: EXPERIMENTAL
Intervention: Public school preschool education
Number of subjects: 38
Study 9578996 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality child care programs
Number of subjects: 38
Study 9578996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-benefit analysis from a randomized trial
Number of subjects: 38
Study 8934727 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC regimen (5‐FU 600 mg/m2 i.v. over 1 hour, DOX 50 mg/m2 i.v. bolus, CPM 400 mg/m2 i.v. bolus)
Number of subjects: 258
Study 8934727 — intervention group
Group type: COMPARATOR
Intervention: FULON regimen (5‐FU 250 mg/m2 per day continuously infused, CPM 300 mg/m2 i.v. bolus, DOX 15 mg/m2 i.v. bolus)
Number of subjects: 258
Study 2693027 — intervention group
Group type: EXPERIMENTAL
Intervention: Gangliosides (100 mg daily, 5 days per week for 12 weeks)
Number of subjects: 26
Study 2693027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 690219 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertion training group
Number of subjects: 80
Study 690219 — intervention group
Group type: COMPARATOR
Intervention: Insight therapy group
Number of subjects: 80
Study 31521754 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, Early Fresh Frozen Plasma Transfusion (LEFT) therapy (5 mL/kg body weight)
Number of subjects: 63
Study 31521754 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NO LEFT group) (5 mL/kg body weight)
Number of subjects: 63
Study 28514264 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐min MOD walking (21 × 2 min bouts at 53% ± 5% HRmax)
Number of subjects: 10
Study 28514264 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐min VIG walking (8 × 2 min bouts at 79% ± 4% HRmax)
Number of subjects: 10
Study 28514264 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min MOD walking (30 min at 71% ± 4% HRmax)
Number of subjects: 10
Study 28514264 — intervention group
Group type: COMPARATOR
Intervention: SIT (9 h of prolonged sitting)
Number of subjects: 10
Study 25724881 — intervention group
Group type: EXPERIMENTAL
Intervention: HydroSoft/HydroFrame coils
Number of subjects: 0
Study 25724881 — intervention group
Group type: COMPARATOR
Intervention: bare platinum coils
Number of subjects: 0
Study 23556410 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq™, A. P. Advance™, King Vision™ (video-laryngoscopes with guiding channel)
Number of subjects: 720
Study 23556410 — intervention group
Group type: COMPARATOR
Intervention: C‐MAC™, GlideScope™, McGrath™ (video-laryngoscopes without integrated tracheal tube guidance)
Number of subjects: 720
Study 23556410 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices used in the trial
Number of subjects: 720
Study 21677600 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus + reduced calcineurin inhibitor (CNI)
Number of subjects: 111
Study 21677600 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus + reduced CNI
Number of subjects: 111
Study 21677600 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA + everolimus
Number of subjects: 111
Study 21677600 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF + everolimus
Number of subjects: 111
Study 21677600 — intervention group
Group type: COMPARATOR
Intervention: standard CNI
Number of subjects: 111
Study 18405405 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride 0.1 per cent nasal spray
Number of subjects: 120
Study 18405405 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride 0.1 per cent nasal spray (in septoplasty patients)
Number of subjects: 120
Study 18405405 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline aerosol
Number of subjects: 120
Study 16380823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Trasylol
Number of subjects: 40
Study 16380823 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass without Trasylol
Number of subjects: 40
Study 14672874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact seeds
Number of subjects: 12
Study 14672874 — intervention group
Group type: COMPARATOR
Intervention: Ground seeds
Number of subjects: 12
Study 10759674 — intervention group
Group type: EXPERIMENTAL
Intervention: Snodgrass procedure
Number of subjects: 60
Study 10759674 — intervention group
Group type: COMPARATOR
Intervention: Mathieu repair
Number of subjects: 60
Study 8885583 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional research designs in pediatric psychopharmacology
Number of subjects: 0
Study 8885583 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative research designs in pediatric psychopharmacology
Number of subjects: 0
Study 8885583 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical research hypothesis evolution to study protocol
Number of subjects: 0
Study 1397215 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Self-Examination (BSE) training
Number of subjects: 120310
Study 1397215 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BSE training)
Number of subjects: 120310
Study 1397215 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE group
Number of subjects: 120310
Study 1397215 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE group and Control group
Number of subjects: 120310
Study 2858711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) at a dosage of 0.75 mg/kg over 90 min
Number of subjects: 129
Study 2858711 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase at a dosage of 1,500,000 IU over 60 min
Number of subjects: 129
Study 2858711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA)
Number of subjects: 129
Study 2858711 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 129
Study 2858711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rt-PA and streptokinase
Number of subjects: 129
Study 30141364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide 0.025% otic solution, administered twice daily for 7 days
Number of subjects: 135
Study 30141364 — intervention group
Group type: COMPARATOR
Intervention: Placebo otic solution, administered twice daily for 7 days
Number of subjects: 135
Study 30141364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide 0.025% otic solution
Number of subjects: 135
Study 30141364 — intervention group
Group type: COMPARATOR
Intervention: Placebo otic solution
Number of subjects: 135
Study 26358163 — intervention group
Group type: EXPERIMENTAL
Intervention: Buns with 10% fenugreek seed powder
Number of subjects: 10
Study 26358163 — intervention group
Group type: EXPERIMENTAL
Intervention: Flatbreads with 10% fenugreek seed powder
Number of subjects: 10
Study 26358163 — intervention group
Group type: COMPARATOR
Intervention: Buns with 0% fenugreek seed powder (control)
Number of subjects: 10
Study 26358163 — intervention group
Group type: COMPARATOR
Intervention: Flatbreads with 0% fenugreek seed powder (control)
Number of subjects: 10
Study 24668360 — intervention group
Group type: EXPERIMENTAL
Intervention: Body awareness therapy (group sessions once a week for eight weeks)
Number of subjects: 46
Study 24668360 — intervention group
Group type: COMPARATOR
Intervention: Usual daily activities (control group)
Number of subjects: 46
Study 22425702 — intervention group
Group type: EXPERIMENTAL
Intervention: SCY‐635 900 mg/d
Number of subjects: 20
Study 20223877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 40
Study 20223877 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 40
Study 18314182 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐gamma 1b plus carboplatin/paclitaxel
Number of subjects: 847
Study 18314182 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel alone
Number of subjects: 847
Study 15527149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartu population
Number of subjects: 805
Study 15527149 — intervention group
Group type: COMPARATOR
Intervention: Uppsala population
Number of subjects: 805
Study 11513186 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. glycyrrhizin treatment three times per week for 4 weeks
Number of subjects: 72
Study 11513186 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. glycyrrhizin treatment six times per week for 4 weeks
Number of subjects: 72
Study 11513186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 9261640 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 47
Study 8427942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymecromone 400 mg infused i.v. over 3 min
Number of subjects: 6
Study 8427942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymecromone 800 mg infused i.v. over 5 min
Number of subjects: 6
Study 8427942 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of hymecromone
Number of subjects: 6
Study 3325721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical stapling (EEA)
Number of subjects: 40
Study 3325721 — intervention group
Group type: COMPARATOR
Intervention: Manual single layer suturing
Number of subjects: 40
Study 3325721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 28597614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hang-clean training program (HCL)
Number of subjects: 58
Study 28597614 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-squat training program (HSQ)
Number of subjects: 58
Study 27810312 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1201
Study 27810312 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1201
Study 25015747 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine 3g daily plus 250 mg clomiphene citrate
Number of subjects: 170
Study 25015747 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 250 mg clomiphene citrate
Number of subjects: 170
Study 20884658 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily
Number of subjects: 2052
Study 20884658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg twice daily
Number of subjects: 2052
Study 20884658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2052
Study 20196678 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Doctor plus provider cueing
Number of subjects: 42
Study 20196678 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study 18672767 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT combined with QHQ
Number of subjects: 81
Study 18672767 — intervention group
Group type: COMPARATOR
Intervention: HAT alone
Number of subjects: 81
Study 16823584 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-verapamil
Number of subjects: 8
Study 16823584 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-verapamil
Number of subjects: 8
Study 16823584 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic verapamil
Number of subjects: 8
Study 16823584 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 12791633 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of protein intake (72 g/d)
Number of subjects: 489
Study 12791633 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 489
Study 11053706 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic AF
Number of subjects: 22
Study 11053706 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 22
Study 8805893 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural blockade
Number of subjects: 50
Study 8805893 — intervention group
Group type: COMPARATOR
Intervention: Penile ring block
Number of subjects: 50
Study 8805893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 50
Study 1628051 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated immunisation schedule (2, 3, and 4 months of age)
Number of subjects: 222
Study 1628051 — intervention group
Group type: COMPARATOR
Intervention: Standard immunisation schedule (3, 4 1/2 to 5, and 8 1/2 to 11 months of age)
Number of subjects: 222
Study 6202967 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (360 mg/day)
Number of subjects: 11
Study 6202967 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg t.i.d.)
Number of subjects: 11
Study 6202967 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 11
Study 31099911 — intervention group
Group type: EXPERIMENTAL
Intervention: Early glucocorticoid (GC) withdrawal
Number of subjects: 0
Study 31099911 — intervention group
Group type: COMPARATOR
Intervention: Chronic glucocorticoid (GC) treatment
Number of subjects: 0
Study 29986928 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP+ group (n=28)
Number of subjects: 61
Study 29986928 — intervention group
Group type: COMPARATOR
Intervention: MEP- group (n=33)
Number of subjects: 61
Study 27390369 — intervention group
Group type: EXPERIMENTAL
Intervention: ATZ/LNG 500 µg/20 µg (low dose)
Number of subjects: 60
Study 27390369 — intervention group
Group type: EXPERIMENTAL
Intervention: ATZ/LNG 1000 µg/30 µg (mid dose)
Number of subjects: 60
Study 27390369 — intervention group
Group type: EXPERIMENTAL
Intervention: ATZ/LNG 1500 µg/40 µg (high dose)
Number of subjects: 60
Study 24275612 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised Stroop task
Number of subjects: 48
Study 24275612 — intervention group
Group type: COMPARATOR
Intervention: General alcohol Stroop task
Number of subjects: 48
Study 24275612 — intervention group
Group type: COMPARATOR
Intervention: Control Stroop task (soft drink-related words)
Number of subjects: 48
Study 21848509 — intervention group
Group type: EXPERIMENTAL
Intervention: Clark's Twin Block with upper labial bow (Group 1)
Number of subjects: 62
Study 21848509 — intervention group
Group type: COMPARATOR
Intervention: Clark's Twin Block without upper labial bow (Group 2)
Number of subjects: 62
Study 19106732 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D index score (0.1 higher score)
Number of subjects: 7348
Study 17897466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (initially seronegative women)
Number of subjects: 1672
Study 17897466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (pregnant women)
Number of subjects: 1672
Study 14532914 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg
Number of subjects: 27
Study 14532914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11547542 — intervention group
Group type: EXPERIMENTAL
Intervention: 28% oxygen for the first 36 postoperative hours (treatment group, n = 13)
Number of subjects: 24
Study 11547542 — intervention group
Group type: COMPARATOR
Intervention: Room air (control group, n = 11)
Number of subjects: 24
Study 9626884 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium (Gd) administered first in the same session (7 patients)
Number of subjects: 13
Study 9626884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxide administered first in the same session (3 patients)
Number of subjects: 13
Study 9626884 — intervention group
Group type: COMPARATOR
Intervention: Gadolinium administered in separate session (3 patients)
Number of subjects: 13
Study 9626884 — intervention group
Group type: COMPARATOR
Intervention: Gadolinium administered first in separate session (3 patients)
Number of subjects: 13
Study 8179371 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (5 g) before cardiopulmonary bypass
Number of subjects: 200
Study 8179371 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin alone (control group)
Number of subjects: 200
Study 3067743 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy at diagnosis followed by supplementary medical therapy (group B)
Number of subjects: 99
Study 3067743 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment followed by trabeculectomy if unsuccessful (group A)
Number of subjects: 99
Study 3067743 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy at diagnosis (group B)
Number of subjects: 99
Study 3067743 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (group A)
Number of subjects: 99
Study 3067743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study 31277913 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive enteral nutrition (EN) via nasogastric (NG) feeding, commenced at 30 ml/h after stem cell infusion, increased to goal as oral intake declined.
Number of subjects: 44
Study 31277913 — intervention group
Group type: COMPARATOR
Intervention: Standard care (parenteral nutrition, PN) commenced when oral intake was ≤60% of requirements for three days.
Number of subjects: 44
Study 28826382 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, promotora‐facilitated 12‐week PA intervention
Number of subjects: 76
Study 27497379 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic consumption (betalactams and amoxicillin)
Number of subjects: 109
Study 27497379 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 109
Study 27497379 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic consumption
Number of subjects: 109
Study 24575737 — intervention group
Group type: EXPERIMENTAL
Intervention: Training dogs to discriminate prostate cancer urine samples from controls
Number of subjects: 10
Study 24575737 — intervention group
Group type: COMPARATOR
Intervention: Control samples (urine from men without prostate cancer)
Number of subjects: 10
Study 23780505 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic (test) formulation of betamethasone injectable suspension
Number of subjects: 24
Study 23780505 — intervention group
Group type: COMPARATOR
Intervention: Branded (reference) formulation of betamethasone injectable suspension
Number of subjects: 24
Study 20094043 — intervention group
Group type: EXPERIMENTAL
Intervention: pramlintide + sibutramine (10 mg q.a.m.)
Number of subjects: 244
Study 20094043 — intervention group
Group type: EXPERIMENTAL
Intervention: pramlintide + phentermine (37.5 mg q.a.m.)
Number of subjects: 244
Study 20094043 — intervention group
Group type: EXPERIMENTAL
Intervention: pramlintide (120 microg t.i.d.)
Number of subjects: 244
Study 20094043 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 244
Study 20094043 — intervention group
Group type: EXPERIMENTAL
Intervention: pramlintide + sibutramine
Number of subjects: 244
Study 20094043 — intervention group
Group type: EXPERIMENTAL
Intervention: pramlintide + phentermine
Number of subjects: 244
Study 18566793 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy including transurethral resection (TUR-B), open partial cystectomy, chemotherapy (intravesical or systemic), local radiation, and minimally invasive interventional therapies.
Number of subjects: 0